News / Taiwan / cnyes
Lotus Pharmaceutical Reports 81% Revenue Surge in August Driven by Alvogen Integration
Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-11
1795
Lotus Pharmaceutical (1795) saw its August revenue climb over 81% year-on-year, bolstered by the integration of Alvogen and strong performance in its B2B business segment.
What Happened
Revenue Growth: Lotus Pharmaceutical (1795) reported August revenue of NT$2.107 billion, marking an 81.68% increase compared to the same period last year. Year-to-date revenue for the first eight months reached NT$22.052 billion, representing a 69.19% year-on-year growth.
Key Drivers: The company's strong performance is largely attributed to the integration of Alvogen and robust momentum in its B2B business. The US market currently accounts for 59% of total revenue, while the B2B segment saw a 2.16-fold increase in revenue driven by new product launches in North America, Europe, and Asia.
Market Presence: Lotus continues to maintain a solid foothold in the Asian market, which contributes approximately 33% of its total revenue. Strategic product launches, including Nintedanib and Enzalutamide, have been instrumental in expanding the company's global B2B footprint.
Stock Performance: Despite the positive revenue results, Lotus shares have faced downward pressure recently, declining over 2% during the trading session. Institutional investors have been net sellers for 11 consecutive sessions, reflecting a cautious sentiment toward the stock's short-term outlook.